Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF^V600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.

ABSTRACT:

Background

The first-line (1L) standard of care for B-Raf proto-oncogene (BRAF)^V600E-mutant metastatic non-small cell lung cancer is BRAF inhibitor dabrafenib with MEK inhibitor trametinib (D + T). Combination therapy with encorafenib and binimetinib (E + B) has recently demonstrated clinical benefit in this setting in the single-arm, phase II PHAROS trial. We evaluated the relative efficacy and safety of E + B versus D + T in 1L using an unanchored matching-adjusted indirect comparison.

Material and methods

Individual patient data for E + B from PHAROS were matched on validated adjustment factors to aggregate data for D + T from Study BRF113928. The relative efficacy and safety of E + B versus D + T were assessed using weighted Cox proportional hazards models for

SUBMITTER: Planchard D 

PROVIDER: S-EPMC12865620 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature